NO178604C - Fremgangsmåte for fremstilling av et preparat for vedvarende og styrt frigivelse av et peptidmedikament - Google Patents

Fremgangsmåte for fremstilling av et preparat for vedvarende og styrt frigivelse av et peptidmedikament

Info

Publication number
NO178604C
NO178604C NO884154A NO884154A NO178604C NO 178604 C NO178604 C NO 178604C NO 884154 A NO884154 A NO 884154A NO 884154 A NO884154 A NO 884154A NO 178604 C NO178604 C NO 178604C
Authority
NO
Norway
Prior art keywords
preparation
sustained
controlled release
peptide drug
peptide
Prior art date
Application number
NO884154A
Other languages
English (en)
Other versions
NO884154D0 (no
NO178604B (no
NO884154L (no
Inventor
Piero Orsolini
Rolland-Yves Mauvernay
Romano Deghenghi
Original Assignee
Debiopharm Sa
Bpd Biopharm Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Debiopharm Sa, Bpd Biopharm Dev Ltd filed Critical Debiopharm Sa
Publication of NO884154D0 publication Critical patent/NO884154D0/no
Publication of NO884154L publication Critical patent/NO884154L/no
Publication of NO178604B publication Critical patent/NO178604B/no
Publication of NO178604C publication Critical patent/NO178604C/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
NO884154A 1987-09-21 1988-09-19 Fremgangsmåte for fremstilling av et preparat for vedvarende og styrt frigivelse av et peptidmedikament NO178604C (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB8722134A GB2209937B (en) 1987-09-21 1987-09-21 Water insoluble polypeptides

Publications (4)

Publication Number Publication Date
NO884154D0 NO884154D0 (no) 1988-09-19
NO884154L NO884154L (no) 1989-03-22
NO178604B NO178604B (no) 1996-01-22
NO178604C true NO178604C (no) 1996-05-02

Family

ID=10624108

Family Applications (2)

Application Number Title Priority Date Filing Date
NO884154A NO178604C (no) 1987-09-21 1988-09-19 Fremgangsmåte for fremstilling av et preparat for vedvarende og styrt frigivelse av et peptidmedikament
NO20050012C NO2005012I2 (no) 1987-09-21 2005-05-03 Triptorelin og farmasoytisk akseptable salter derav

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20050012C NO2005012I2 (no) 1987-09-21 2005-05-03 Triptorelin og farmasoytisk akseptable salter derav

Country Status (23)

Country Link
US (2) US5192741A (no)
JP (1) JPH0713023B2 (no)
AT (1) AT397035B (no)
AU (1) AU611944B2 (no)
BE (1) BE1001685A5 (no)
CA (1) CA1326438C (no)
CH (1) CH675968A5 (no)
DE (2) DE3822459C2 (no)
DK (1) DK175311B1 (no)
ES (1) ES2009346A6 (no)
FI (1) FI96919C (no)
FR (1) FR2620621B1 (no)
GB (1) GB2209937B (no)
GR (1) GR1002244B (no)
IE (1) IE60608B1 (no)
IL (1) IL87790A (no)
IT (1) IT1225148B (no)
LU (1) LU87340A1 (no)
NL (1) NL193818C (no)
NO (2) NO178604C (no)
PT (1) PT88557B (no)
SE (1) SE503406C2 (no)
ZA (1) ZA886827B (no)

Families Citing this family (196)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4997815A (en) * 1988-11-01 1991-03-05 Children's Hospital Medical Center Of Northern California Method for augmenting fetal hemoglobin by treatment with activin and/or inhibin
HU221294B1 (en) * 1989-07-07 2002-09-28 Novartis Ag Process for producing retarde compositions containing the active ingredient in a polymeric carrier
PH30995A (en) * 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
US5538739A (en) * 1989-07-07 1996-07-23 Sandoz Ltd. Sustained release formulations of water soluble peptides
CH679207A5 (no) * 1989-07-28 1992-01-15 Debiopharm Sa
CH681425A5 (no) * 1990-11-14 1993-03-31 Debio Rech Pharma Sa
US5439688A (en) * 1989-07-28 1995-08-08 Debio Recherche Pharmaceutique S.A. Process for preparing a pharmaceutical composition
US5225205A (en) * 1989-07-28 1993-07-06 Debiopharm S.A. Pharmaceutical composition in the form of microparticles
DE59003337D1 (de) * 1989-10-16 1993-12-09 Danubia Petrochem Polymere Pressling mit retardierter Wirkstofffreisetzung.
DE3935736A1 (de) * 1989-10-27 1991-05-02 Chemie Linz Deutschland Pressling mit retardierter wirkstofffreisetzung
CA2046830C (en) * 1990-07-19 1999-12-14 Patrick P. Deluca Drug delivery system involving inter-action between protein or polypeptide and hydrophobic biodegradable polymer
IE912365A1 (en) * 1990-07-23 1992-01-29 Zeneca Ltd Continuous release pharmaceutical compositions
IT1243390B (it) * 1990-11-22 1994-06-10 Vectorpharma Int Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione.
YU48420B (sh) * 1991-03-25 1998-07-10 Hoechst Aktiengesellschaft Postupak za dobijanje biološki razgradljivih mikročestica sa dugotrajnim delovanjem
CH683149A5 (fr) * 1991-07-22 1994-01-31 Debio Rech Pharma Sa Procédé pour la préparation de microsphères en matériau polymère biodégradable.
US6013853A (en) * 1992-02-14 2000-01-11 The University Of Texas System Continuous release polymeric implant carrier
US5876452A (en) * 1992-02-14 1999-03-02 Board Of Regents, University Of Texas System Biodegradable implant
US5912015A (en) 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
WO1993017668A1 (en) * 1992-03-12 1993-09-16 Alkermes Controlled Therapeutics, Inc. Controlled release acth containing microspheres
US6514533B1 (en) 1992-06-11 2003-02-04 Alkermas Controlled Therapeutics, Inc. Device for the sustained release of aggregation-stabilized, biologically active agent
US20030035845A1 (en) * 1992-06-11 2003-02-20 Zale Stephen E. Composition for sustained release of non-aggregated erythropoietin
US5674534A (en) * 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5716644A (en) * 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5711968A (en) * 1994-07-25 1998-01-27 Alkermes Controlled Therapeutics, Inc. Composition and method for the controlled release of metal cation-stabilized interferon
DE4223169C1 (de) * 1992-07-10 1993-11-25 Ferring Arzneimittel Gmbh Verfahren zur Mikroverkapselung wasserlöslicher Wirkstoffe
FR2693905B1 (fr) * 1992-07-27 1994-09-02 Rhone Merieux Procédé de préparation de microsphères pour la libération prolongée de l'hormone LHRH et ses analogues, microsphères et formulations obtenues.
DK0674506T3 (da) 1992-12-02 2001-01-08 Alkermes Inc Væksthormonholdige mikrosfærer med styret frigivelse
RU2128055C1 (ru) * 1992-12-07 1999-03-27 Такеда Кемикал Индастриз Лтд. Фармацевтическая композиция замедленного высвобождения и способ ее получения
UA61046C2 (en) 1992-12-07 2003-11-17 Takeda Chemical Industries Ltd Sustained-release preparation and method for its manufacture
TW333456B (en) * 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
US5981719A (en) 1993-03-09 1999-11-09 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US6090925A (en) 1993-03-09 2000-07-18 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
JP2944419B2 (ja) * 1993-05-10 1999-09-06 ノバルティス アクチエンゲゼルシャフト 持続性遊離組成物中の薬理学的活性成分の安定
US5635216A (en) * 1993-12-16 1997-06-03 Eli Lilly And Company Microparticle compositions containing peptides, and methods for the preparation thereof
US6087324A (en) * 1993-06-24 2000-07-11 Takeda Chemical Industries, Ltd. Sustained-release preparation
DE4342092B4 (de) * 1993-12-09 2007-01-11 Zentaris Gmbh Langwirkende Injektionssuspension und Verfahren zur Herstellung
CA2178592C (en) * 1993-12-09 2009-07-28 Zentaris Gmbh Long-acting injection suspensions and a process for their preparation
US5569468A (en) * 1994-02-17 1996-10-29 Modi; Pankaj Vaccine delivery system for immunization, using biodegradable polymer microspheres
US5417982A (en) * 1994-02-17 1995-05-23 Modi; Pankaj Controlled release of drugs or hormones in biodegradable polymer microspheres
US20020193338A1 (en) * 1994-02-18 2002-12-19 Goldstein Steven A. In vivo gene transfer methods for wound healing
US5942496A (en) 1994-02-18 1999-08-24 The Regent Of The University Of Michigan Methods and compositions for multiple gene transfer into bone cells
US5962427A (en) 1994-02-18 1999-10-05 The Regent Of The University Of Michigan In vivo gene transfer methods for wound healing
US6074840A (en) 1994-02-18 2000-06-13 The Regents Of The University Of Michigan Recombinant production of latent TGF-beta binding protein-3 (LTBP-3)
US5763416A (en) 1994-02-18 1998-06-09 The Regent Of The University Of Michigan Gene transfer into bone cells and tissues
US6551618B2 (en) * 1994-03-15 2003-04-22 University Of Birmingham Compositions and methods for delivery of agents for neuronal regeneration and survival
US5430021A (en) * 1994-03-18 1995-07-04 Pharmavene, Inc. Hydrophobic drug delivery systems
CA2187353C (en) * 1994-04-08 2007-05-22 Gerald L. Yewey Liquid delivery compositions
IE75744B1 (en) * 1995-04-03 1997-09-24 Elan Corp Plc Controlled release biodegradable micro- and nanospheres containing cyclosporin
US5922253A (en) * 1995-05-18 1999-07-13 Alkermes Controlled Therapeutics, Inc. Production scale method of forming microparticles
ATE268591T1 (de) 1995-06-27 2004-06-15 Takeda Chemical Industries Ltd Verfahren zur herstellung von zubereitungen mit verzögerter freisetzung
CA2230494A1 (en) * 1995-08-31 1997-03-06 Alkermes Controlled Therapeutics Inc. Composition for sustained release of an agent
US5942253A (en) * 1995-10-12 1999-08-24 Immunex Corporation Prolonged release of GM-CSF
FR2748205A1 (fr) * 1996-05-06 1997-11-07 Debio Rech Pharma Sa Compositions pharmaceutiques pour la liberation controlee de principes actifs insolubles
US5817343A (en) * 1996-05-14 1998-10-06 Alkermes, Inc. Method for fabricating polymer-based controlled-release devices
US5817627A (en) 1996-06-14 1998-10-06 Theratechnologies Inc. Long-acting galenical formulation for GRF peptides
US5945128A (en) * 1996-09-04 1999-08-31 Romano Deghenghi Process to manufacture implants containing bioactive peptides
US20070185032A1 (en) * 1996-12-11 2007-08-09 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
US5968895A (en) 1996-12-11 1999-10-19 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
ES2158611T3 (es) 1996-12-20 2001-09-01 Alza Corp Composicion en gel inyectable con efecto retard y procedimiento para la preparacion de dicha composicion.
AU5678398A (en) * 1997-01-29 1998-08-18 Takeda Chemical Industries Ltd. Sustained-release microspheres, their production and use
ATE316779T1 (de) * 1997-06-04 2006-02-15 Debio Rech Pharma Sa Implantate zur gesteuerten freisetzung von pharmazeutischen wirkstoffen und verfahren zur herstellung
US7923250B2 (en) 1997-07-30 2011-04-12 Warsaw Orthopedic, Inc. Methods of expressing LIM mineralization protein in non-osseous cells
EP1007673B1 (en) 1997-07-30 2008-12-17 Emory University Novel bone mineralization proteins, dna, vectors, expression systems
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
US6617321B2 (en) 1997-09-30 2003-09-09 Eli Lilly And Company 2-methyl-thieno-benzodiazepine formulation
US7128927B1 (en) 1998-04-14 2006-10-31 Qlt Usa, Inc. Emulsions for in-situ delivery systems
US6143314A (en) * 1998-10-28 2000-11-07 Atrix Laboratories, Inc. Controlled release liquid delivery compositions with low initial drug burst
IT1304152B1 (it) * 1998-12-10 2001-03-08 Mediolanum Farmaceutici Srl Composizioni comprendenti un peptide ed acido polilattico-glicolicoatte alla preparazione di impianti sottocutanei aventi un prolungato
KR100321854B1 (ko) * 1998-12-30 2002-08-28 동국제약 주식회사 루테이나이징 호르몬 릴리싱 호르몬 동족체를 함유하는 장기 서방출성 미립구 및 그의 제조방법
US7018654B2 (en) * 1999-03-05 2006-03-28 New River Pharmaceuticals Inc. Pharmaceutical composition containing an active agent in an amino acid copolymer structure
US6716452B1 (en) 2000-08-22 2004-04-06 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
WO2000054797A2 (en) 1999-03-17 2000-09-21 Novartis Ag Pharmaceutical compositions comprising tgf-beta
ES2169980B1 (es) 1999-12-17 2003-11-01 Lipotec Sa Microcapsulas para la liberacion prolongada de farmacos.
US6465425B1 (en) * 2000-02-10 2002-10-15 Alkermes Controlled Therapeutics, Inc. Microencapsulation and sustained release of biologically active acid-stable or free sulfhydryl-containing proteins
US20030211974A1 (en) * 2000-03-21 2003-11-13 Brodbeck Kevin J. Gel composition and methods
US6362308B1 (en) * 2000-08-10 2002-03-26 Alkermes Controlled Therapeutics Inc. Ii Acid end group poly(d,l-lactide-co-glycolide) copolymers high glycolide content
SE517422C2 (sv) * 2000-10-06 2002-06-04 Bioglan Ab Farmaceutiskt acceptabel stärkelse
EP1328258B1 (en) * 2000-10-06 2008-10-01 Pacira Pharmaceuticals Inc A controlled-release, parenterally administrable microparticle preparation
SE517421C2 (sv) 2000-10-06 2002-06-04 Bioglan Ab Mikropartiklar, lämpade för parenteral administration, väsentligen bestående av stärkelse med minst 85 % amylopektin och med reducerad molekylvikt, samt framställning därav
US8394813B2 (en) 2000-11-14 2013-03-12 Shire Llc Active agent delivery systems and methods for protecting and administering active agents
SE518007C2 (sv) 2000-11-16 2002-08-13 Bioglan Ab Förfarande för framställning av mikropartiklar
SE518008C2 (sv) * 2000-11-16 2002-08-13 Bioglan Ab Parenteralt administrerbara mikropartiklar och förfarande för framställning av desamma
ATE373471T1 (de) * 2000-12-27 2007-10-15 Ares Trading Sa Lipidmikropartikel mittels kryogenischer mikronisierung
US20070142325A1 (en) * 2001-01-08 2007-06-21 Gustavsson Nils O Starch
WO2003000156A1 (en) 2001-06-22 2003-01-03 Southern Biosystems, Inc. Zero-order prolonged release coaxial implants
CA2456034A1 (en) * 2001-08-03 2003-02-20 Takeda Chemical Industries, Ltd. Sustained-release medicines
US20060014697A1 (en) * 2001-08-22 2006-01-19 Travis Mickle Pharmaceutical compositions for prevention of overdose or abuse
US7169752B2 (en) * 2003-09-30 2007-01-30 New River Pharmaceuticals Inc. Compounds and compositions for prevention of overdose of oxycodone
US7105181B2 (en) * 2001-10-05 2006-09-12 Jagotec, Ag Microparticles
US20040043938A1 (en) * 2001-11-06 2004-03-04 Dinesh Purandare Combination therapy for estrogen-dependent disorders
SE0201599D0 (sv) * 2002-03-21 2002-05-30 Skyepharma Ab Microparticles
US20090035260A1 (en) * 2002-07-29 2009-02-05 Therapicon Srl Enhanced nasal composition of active peptide
US7658998B2 (en) * 2003-01-22 2010-02-09 Alkermes Controlled Therapeutics, Inc. Method of preparing sustained release microparticles
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
SI1594517T1 (sl) 2003-01-28 2007-10-31 Microbia Inc Sestavki za zdravljenje gastrointestinalnih motenj
GB0304726D0 (en) * 2003-03-01 2003-04-02 Ardana Bioscience Ltd New Process
JP4489761B2 (ja) 2003-03-14 2010-06-23 ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク マイクロ流体無膜交換装置を有する血液ベースの治療のためのシステム及び方法
US20060076295A1 (en) * 2004-03-15 2006-04-13 The Trustees Of Columbia University In The City Of New York Systems and methods of blood-based therapies having a microfluidic membraneless exchange device
PT1615959E (pt) * 2003-04-10 2013-08-29 Evonik Corp Um método para a produção de micropartículas à base de emulsão
US20070207211A1 (en) * 2003-04-10 2007-09-06 Pr Pharmaceuticals, Inc. Emulsion-based microparticles and methods for the production thereof
US20060193825A1 (en) * 2003-04-29 2006-08-31 Praecis Phamaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
US20050112087A1 (en) * 2003-04-29 2005-05-26 Musso Gary F. Pharmaceutical formulations for sustained drug delivery
EP2462896A1 (en) * 2003-07-15 2012-06-13 PR Pharmaceuticals Inc. Method for the preparation of controlled release formulations
US8900636B2 (en) * 2003-07-23 2014-12-02 Evonik Corporation Controlled release compositions
US6987111B2 (en) * 2003-08-06 2006-01-17 Alkermes Controlled Therapeutics, Ii Aripiprazole, olanzapine and haloperidol pamoate salts
US7309232B2 (en) * 2003-10-10 2007-12-18 Dentigenix Inc. Methods for treating dental conditions using tissue scaffolds
EP1682537B1 (en) 2003-11-05 2012-03-28 SARcode Bioscience Inc. Modulators of cellular adhesion
ITMI20040235A1 (it) * 2004-02-13 2004-05-13 Therapicon Srl Preparazione farmaceutica per il cavo orale
ES2400687T3 (es) * 2004-04-23 2013-04-11 Amgen Inc. Formulaciones de liberación sostenida
GB0412866D0 (en) * 2004-06-09 2004-07-14 Novartis Ag Organic compounds
CA2575988C (en) 2004-08-04 2014-02-18 Brookwood Pharmaceuticals, Inc. Methods for manufacturing delivery devices and devices thereof
ES2255426B1 (es) * 2004-10-19 2007-08-16 Gp Pharm, S.A. Formulacion farmaceutica que comprende microcapsulas de estatinas suspendidas en ester alquilicos de acidos grasos poliinsaturados (pufa).
EP1674082A1 (de) 2004-12-22 2006-06-28 Zentaris GmbH Verfahren zur Herstellung von sterilen Suspensionen oder Lyophilisaten schwerlöslicher basischer Peptidkomplexe, diese enthaltende pharmazeutische Formulierungen sowie ihre Verwendung als Arzneimittel
US7932249B2 (en) * 2005-01-05 2011-04-26 Eli Lilly And Company Olanzapine pamoate dihydrate
EP2206495B1 (en) 2005-01-14 2012-11-21 Camurus AB Topical bioadhesive formulations
US9649382B2 (en) 2005-01-14 2017-05-16 Camurus Ab Topical bioadhesive formulations
DE602005026998D1 (de) * 2005-01-14 2011-04-28 Camurus Ab Somatostatin-analog-formulierungen
US9060935B2 (en) * 2005-01-21 2015-06-23 Camurus Ab Pharmaceutical lipid compositions
EP1846437A1 (en) * 2005-02-01 2007-10-24 Attenuon, LLC ACID ADDITION SALTS OF Ac-PHSCN-NH2
JP2008539260A (ja) * 2005-04-25 2008-11-13 アムジエン・インコーポレーテツド ポロゲンを含む生分解性プチド徐放性組成物
DK1881823T3 (en) * 2005-05-17 2015-03-02 Sarcode Bioscience Inc COMPOSITION AND PROCEDURES FOR TREATMENT OF EYE DISORDERS
CA2609810C (en) * 2005-06-06 2012-05-22 Camurus Ab Glp-1 analogue formulations
CN101258163B (zh) * 2005-06-30 2013-08-21 益普生制药股份有限公司 Glp-1药物组合物
US7942867B2 (en) * 2005-11-09 2011-05-17 The Invention Science Fund I, Llc Remotely controlled substance delivery device
KR100722607B1 (ko) 2006-05-11 2007-05-28 주식회사 펩트론 분산성 및 주사 투여능이 향상된 서방성 미립구의 제조방법
US7403325B2 (en) * 2006-05-19 2008-07-22 Xerox Corporation Electrophoretic display device
BRPI0711896A2 (pt) 2006-05-22 2012-07-17 Univ Columbia sistemas e métodos de troca sem membrana microfluida usando filtração da extração de correntes de saìda de fluido.
US20080075777A1 (en) * 2006-07-31 2008-03-27 Kennedy Michael T Apparatus and methods for preparing solid particles
US8211905B1 (en) 2007-05-22 2012-07-03 Pisgah Laboratories, Inc. Opioid salts and formulations exhibiting anti-abuse and anti-dose dumping properties
US20080293695A1 (en) * 2007-05-22 2008-11-27 David William Bristol Salts of physiologically active and psychoactive alkaloids and amines simultaneously exhibiting bioavailability and abuse resistance
US8039461B1 (en) 2006-11-10 2011-10-18 Pisgah Laboratories, Inc. Physical states of a pharmaceutical drug substance
US7858663B1 (en) 2007-10-31 2010-12-28 Pisgah Laboratories, Inc. Physical and chemical properties of thyroid hormone organic acid addition salts
US7718649B1 (en) 2006-11-10 2010-05-18 Pisgah Labs, Inc. Physical states of a pharmaceutical drug substance
US8329720B1 (en) 2007-05-22 2012-12-11 Pisgah Laboratories, Inc. Opioid salts and formulations exhibiting abuse deterrent and anti-dose dumping properties
US9421266B2 (en) 2007-05-22 2016-08-23 Pisgah Laboratories, Inc. Safety of pseudoephedrine drug products
US10183001B1 (en) 2007-05-22 2019-01-22 Pisgah Laboratories, Inc. Opioid and attention deficit hyperactivity disorder medications possessing abuse deterrent and anti-dose dumping safety features
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
AU2008261102B2 (en) 2007-06-04 2013-11-28 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US20100120694A1 (en) 2008-06-04 2010-05-13 Synergy Pharmaceuticals, Inc. Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders
FI2500014T4 (fi) * 2007-06-06 2025-04-08 Debiopharm Int Sa Mikropartikkeleista valmistettu hitaasti vapauttava farmaseuttinen koostumus
GB0711656D0 (en) * 2007-06-15 2007-07-25 Camurus Ab Formulations
GB0716385D0 (en) 2007-08-22 2007-10-03 Camurus Ab Formulations
AU2008317473B2 (en) 2007-10-19 2014-07-17 Bausch + Lomb Ireland Limited Compositions and methods for treatment of diabetic retinopathy
JP5502751B2 (ja) 2007-12-20 2014-05-28 エボニック コーポレイション 低残留溶媒濃度を有する微粒子を調製するためのプロセス
CN102065926A (zh) * 2008-02-04 2011-05-18 纽约市哥伦比亚大学理事会 流体分离装置、系统和方法
US8883863B1 (en) 2008-04-03 2014-11-11 Pisgah Laboratories, Inc. Safety of psuedoephedrine drug products
WO2009139817A2 (en) 2008-04-15 2009-11-19 Sarcode Corporation Crystalline pharmaceutical and methods of preparation and use thereof
CN102065893A (zh) * 2008-04-15 2011-05-18 萨可德公司 Lfa-1拮抗剂向胃肠系统的递送
ES2624828T3 (es) 2008-07-16 2017-07-17 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
CA2731374C (en) 2008-07-30 2019-04-02 Mesynthes Limited Tissue scaffolds derived from forestomach extracellular matrix
GB0815435D0 (en) 2008-08-22 2008-10-01 Camurus Ab Formulations
ES2550308T3 (es) 2008-08-29 2015-11-06 Genzyme Corporation Formulaciones peptídicas de liberación controlada
US20100062057A1 (en) * 2008-09-10 2010-03-11 Pronova BioPharma Norge AS. Formulation
BRPI1009431A2 (pt) 2009-03-09 2016-03-01 Pronova Biopharma Norge As pré-concentrados farmacêuticos e de suplemento alimentar, sistemas de liberação de droga, método de tratamento de pelo menos um problema de saúde em sujeito em necessidade do mesmo e método e sistema
WO2011037953A2 (en) * 2009-09-22 2011-03-31 Surmodics Pharmaceuticals, Inc. Implant devices having varying bioactive agent loading configurations
WO2011050175A1 (en) 2009-10-21 2011-04-28 Sarcode Corporation Crystalline pharmaceutical and methods of preparation and use thereof
ES2363964B1 (es) 2009-11-20 2012-08-22 Gp Pharm, S.A. Cápsulas de principios activos farmacéuticos y ésteres de ácidos grasos poliinsaturados.
ES2364011B1 (es) 2009-11-20 2013-01-24 Gp Pharm, S.A. Cápsulas de principios activos farmacéuticos y ésteres de ácidos grasos poliinsaturados para el tratamiento de enfermedades cardiovasculares.
ES2363965B1 (es) 2009-11-20 2013-01-24 Gp Pharm S.A. Cápsulas de principios activos betabloqueantes y ésteres de ácidos grasos poliinsaturados.
WO2011078712A1 (pt) 2009-12-23 2011-06-30 Dafiante Farmacêutica S.A. Composição de combinação útil para tratamento de doenças cardiovasculares
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
BR112012016459B1 (pt) * 2010-01-04 2020-01-14 Mapi Pharma Ltd composto farmacêutico parenteral de ação prolongada, composição farmacêutica e sal de glatirâmero farmaceuticamente aceitável
ES2383271B1 (es) 2010-03-24 2013-08-01 Lipotec S.A. Procedimiento de tratamiento de fibras y/o materiales textiles
ES2385240B1 (es) 2010-07-26 2013-09-23 Gp-Pharm, S.A. Cápsulas de principios activos farmacéuticos y ácidos grasos poliinsaturados para el tratamiento de enfermedades de la próstata.
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
CA2835018C (en) 2011-05-04 2020-04-21 Balance Therapeutics, Inc. Pentylenetetrazole derivatives
WO2013072767A1 (en) 2011-11-18 2013-05-23 Pronova Biopharma Norge As Compositions and preconcentrates comprising at least one salicylate and omega-3 fatty acid oil mixture
US9585896B2 (en) 2012-04-04 2017-03-07 Pronova Biopharma Norge As Compositions comprising omega-3 fatty acids and vitamin D for psoriasis, and methods and uses thereof
US20150079164A1 (en) 2012-04-04 2015-03-19 Pronova Biopharma Norge As Compositions comprising omega-3 fatty acids and vitamin d for acne vulgaris and/or eczema, and methods and uses thereof
PL2851085T3 (pl) * 2012-05-14 2019-12-31 Teijin Limited Kompozycja białka sterylizowana promieniowaniem
EA035495B1 (ru) 2012-05-25 2020-06-25 Камурус Аб Состав-предшественник, содержащий агонист рецепторов соматостатина, способ лечения путем его введения, его применение, предварительно заполненное устройство, содержащее его, и набор, содержащий указанное устройство
WO2014018748A1 (en) 2012-07-25 2014-01-30 Sarcode Bioscience Inc. Lfa-1 inhibitor and polymorph thereof
US9545446B2 (en) 2013-02-25 2017-01-17 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
AR094941A1 (es) 2013-02-28 2015-09-09 Olaf Hustvedt Svein Una composición que comprende un compuesto lipídico, un triglicérido y un tensioactivo, y métodos para usarla
FR3002736B1 (fr) 2013-03-04 2015-06-26 Virbac Composition orale nutritionnelle et medicamenteuse a usage veterinaire
FR3002735B1 (fr) * 2013-03-04 2015-07-03 Virbac Composition orale nutritionnelle et medicamenteuse a usage veterinaire
HK1220611A1 (zh) 2013-03-15 2017-05-12 Bausch Health Ireland Limited 用於治疗胃肠道病症的组成物
US9708367B2 (en) 2013-03-15 2017-07-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
EP3054969B1 (en) 2013-10-10 2021-03-10 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of opioid induced dysfunctions
US10046058B2 (en) 2014-12-02 2018-08-14 Rezolute, Inc. Use of hydrophobic organic acids to increase hydrophobicity of proteins and protein conjugates
US9687526B2 (en) 2015-01-30 2017-06-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9750785B2 (en) 2015-01-30 2017-09-05 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9925233B2 (en) 2015-01-30 2018-03-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9375478B1 (en) 2015-01-30 2016-06-28 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9744209B2 (en) 2015-01-30 2017-08-29 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9937223B2 (en) 2015-01-30 2018-04-10 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
KR20180029235A (ko) 2015-07-15 2018-03-20 인터내셔날 애드밴스드 리서치 센터 폴 파우더 메탈러지 앤드 뉴 머테리얼스 (에이알씨아이) 효율이 향상된 실리카 에어로겔 단열 제품을 생산하기 위한 개선된 공정
CA3009814A1 (en) 2016-01-11 2017-07-20 Synergy Pharmaceuticals, Inc. Formulations and methods for treating ulcerative colitis
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
AU2017319728B2 (en) 2016-08-31 2024-09-05 Mapi Pharma Ltd Depot systems comprising glatiramer acetate
AU2018242998B2 (en) 2017-03-26 2023-11-02 Mapi Pharma Ltd. Glatiramer depot systems for treating progressive forms of multiple sclerosis
CN111315365A (zh) 2017-09-26 2020-06-19 纳奥米有限公司 用于通过双乳液技术制备微粒的方法
CN110123658B (zh) * 2019-05-22 2022-07-15 上海璞萃生物科技有限公司 一种具有自组装聚集体结构的超分子多肽及其制备方法
IT202000017191A1 (it) 2020-07-15 2022-01-15 Xbrane Biopharma Ab Procedimento senza acqua per preparare una composizione farmaceutica per un rilascio più prolungato e controllato di triptorelina o di un suo sale
CN116803378B (zh) * 2023-08-24 2023-11-17 北京福元医药股份有限公司 一种格列齐特缓释片剂及其制备方法
WO2026050206A1 (en) 2024-08-27 2026-03-05 Ironwood Pharmaceuticals, Inc. Combinations of glp-1 and guanylate cyclase c (gc-c) receptor agonists

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4010125A (en) * 1975-06-12 1977-03-01 Schally Andrew Victor [D-Trp6 ]-LH-RH and intermediates therefor
US4622244A (en) * 1979-09-04 1986-11-11 The Washington University Process for preparation of microcapsules
US4293539A (en) * 1979-09-12 1981-10-06 Eli Lilly And Company Controlled release formulations and method of treatment
US4341767A (en) * 1980-10-06 1982-07-27 Syntex Inc. Nonapeptide and decapeptide analogs of LHRH, useful as LHRH antagonists
PH19942A (en) * 1980-11-18 1986-08-14 Sintex Inc Microencapsulation of water soluble polypeptides
US4675189A (en) * 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
IE52535B1 (en) * 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
ATE37983T1 (de) * 1982-04-22 1988-11-15 Ici Plc Mittel mit verzoegerter freigabe.
US4667014A (en) * 1983-03-07 1987-05-19 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide analogs of LHRH, useful as LHRH antagonists
CH660488A5 (en) * 1982-12-17 1987-04-30 Sandoz Ag (Co)oligomeric hydroxycarboxylic acid derivatives, the preparation thereof, and the use thereof in pharmaceutical compositions
CH661206A5 (fr) * 1983-09-23 1987-07-15 Debiopharm Sa Procede pour la preparation d'un medicament destine au traitement de maladies hormonodependantes.
JPS60100516A (ja) * 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
US4547370A (en) * 1983-11-29 1985-10-15 The Salk Institute For Biological Studies GnRH Antagonists
US4708861A (en) * 1984-02-15 1987-11-24 The Liposome Company, Inc. Liposome-gel compositions
US4632979A (en) * 1984-06-18 1986-12-30 Tulane Educational Fund Therapeutic LHRH analogs
GB8416234D0 (en) * 1984-06-26 1984-08-01 Ici Plc Biodegradable amphipathic copolymers
US4647653A (en) * 1984-08-23 1987-03-03 Tulane Educational Fund Therapeutic peptides
ZA855567B (en) * 1984-08-31 1986-03-26 Salk Inst For Biological Studi Insulin-selective somatostatin analogs
CH660302A5 (fr) * 1984-10-17 1987-04-15 Debiopharm Sa Procede de micro-encapsulation en phase heterogene de substances medicamenteuses hydrosolubles.
JPS61172813A (ja) * 1985-01-28 1986-08-04 Japan Atom Energy Res Inst ポリ乳酸を担体とする徐放性複合体の製造方法
EP0190833B1 (en) * 1985-02-07 1991-03-27 Takeda Chemical Industries, Ltd. Method for producing microcapsule
US4677193A (en) * 1985-02-22 1987-06-30 The Salk Institute For Biological Studies Peptides containing an aliphatic-aromatic ketone side chain
US4666704A (en) * 1985-05-24 1987-05-19 International Minerals & Chemical Corp. Controlled release delivery system for macromolecules
IL79134A (en) * 1985-07-29 1991-06-10 American Cyanamid Co Continuous release peptide implants for parenteral administration
US4962091A (en) * 1986-05-23 1990-10-09 Syntex (U.S.A.) Inc. Controlled release of macromolecular polypeptides
US4897268A (en) * 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
US5089471A (en) * 1987-10-01 1992-02-18 G. D. Searle & Co. Peptidyl beta-aminoacyl aminodiol carbamates as anti-hypertensive agents
DE3734223A1 (de) * 1987-10-09 1989-04-20 Boehringer Ingelheim Kg Implantierbares, biologisch abbaubares wirkstofffreigabesystem
CA2012901A1 (en) * 1989-04-05 1990-10-05 Quirico Branca Amino acid derivatives

Also Published As

Publication number Publication date
SE8803321L (sv) 1989-03-22
DE3822459C2 (de) 1994-07-07
NO884154D0 (no) 1988-09-19
FI884297A0 (fi) 1988-09-19
NO178604B (no) 1996-01-22
DE3822459A1 (de) 1989-03-30
GR1002244B (en) 1996-04-22
IE60608B1 (en) 1994-07-27
NO2005012I2 (no) 2008-12-01
IT1225148B (it) 1990-11-02
PT88557B (pt) 1992-11-30
ES2009346A6 (es) 1989-09-16
GB2209937B (en) 1991-07-03
BE1001685A5 (fr) 1990-02-06
ZA886827B (en) 1989-05-30
JPH0713023B2 (ja) 1995-02-15
US5776885A (en) 1998-07-07
AU2232688A (en) 1989-03-23
DE122004000023I2 (de) 2009-05-07
NL193818B (nl) 2000-08-01
DK518988A (da) 1989-03-22
PT88557A (pt) 1988-10-01
JPH01121222A (ja) 1989-05-12
DK518988D0 (da) 1988-09-16
FR2620621B1 (fr) 1993-02-19
SE503406C2 (sv) 1996-06-10
LU87340A1 (fr) 1989-04-06
NL193818C (nl) 2000-12-04
IL87790A0 (en) 1989-03-31
FI884297L (fi) 1989-03-22
ATA223488A (de) 1993-06-15
GB2209937A (en) 1989-06-01
AT397035B (de) 1994-01-25
IL87790A (en) 1992-05-25
IT8805213A0 (it) 1988-09-20
CA1326438C (en) 1994-01-25
FI96919C (fi) 1996-09-25
FI96919B (fi) 1996-06-14
CH675968A5 (no) 1990-11-30
SE8803321D0 (sv) 1988-09-20
NL8802323A (nl) 1989-04-17
AU611944B2 (en) 1991-06-27
US5192741A (en) 1993-03-09
IE882727L (en) 1989-03-21
GR880100619A (el) 1989-06-22
DK175311B1 (da) 2004-08-16
GB8722134D0 (en) 1987-10-28
FR2620621A1 (fr) 1989-03-24
NO884154L (no) 1989-03-22

Similar Documents

Publication Publication Date Title
NO178604C (no) Fremgangsmåte for fremstilling av et preparat for vedvarende og styrt frigivelse av et peptidmedikament
NO983923L (no) FremgangsmÕte for fremstilling av et farmas°ytisk preparat med forlenget frigivelse
NO882103D0 (no) Fremgangsmaate for fremstilling av et farmasoeytisk preparat
NO179357C (no) Fremgangsmåte for fremstilling av et farmasöytisk preparat med forlenget frigivelse
PT86870A (pt) Pharmaceutical tablet pharmaceutical granulate and process for their preparation
NO922886D0 (no) Preparat for vedvarende og styrt frigivelse av medikamentsubstans og fremgangsmaate for fremstilling av preparatet
NO892826D0 (no) Fremgangsmaate for fremstilling av et farmasoeytisk preparat for aa forhindre seksuelt overfoerbare sykdommer.
NO170940C (no) Analogifremgangsmaate for fremstilling av en terapeutisk virksom blanding av hepariner
FI885101L (fi) Menetelmä lääkettä säännöstellysti vapauttavan annostusmuodon valmistamiseksi
NO903264L (no) Fremgangsmaate for fremstilling av et farmasoeytisk preparat i form av mikropartikler.
FI881900A7 (fi) Analogiamenetelmä terapeuttisesti käyttökelpoisten substituoitujen imidatsolyylialkyylipiperatsiini- ja -diatsepiinijohdannaisten valmistamiseksi
NO884052D0 (no) Fremgangsmaate for fremstilling av et terapeutisk preparat.
NO173334C (no) Analogifremgangsm}te for fremstilling av terapeutisk aktive alkylaminoalkylenderivater 2H-1-benzopyraner
NO173590C (no) Fremgangsmaate for fremstilling av et stabilt nikorandilholdig farmasoeytisk preparat
FI890283A0 (fi) Menetelmä terapeuttisesti käyttökelpoisten 25-hydroksi-vitamiinin D-johdannaisten valmistamiseksi
NO901232D0 (no) Fremgangsmaate for fremstilling av et farmasoeytisk preparat
FI894604L (fi) Menetelmä uusien terapeuttisesti käyttökelpoisten pyridyyli- ja pyrimidyylipiperatsiinijohdannaisten valmistamiseksi
NO177485C (no) Fremgangsmåte for fremstilling av et farmasöytisk inhalasjonspreparat
NO176100C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive oksodihydropyridyl- og oksodihydropyridazinylkromanderivater
NO168100C (no) Analogifremgangsmaate for fremstilling av et terapeutisk aktivt fenolderivat
NO175963C (no) Fremgangsmåte for fremstilling av et vannopplöselig antibiotisk preparat
NO179396C (no) Fremgangsmåte ved fremstilling av en medikamentell administreringsform for drövtyggere
NO178883C (no) Fremgangsmåte for fremstilling av et farmasöytisk preparat for behandling av tonsillitt
NO177750C (no) Analogifremgangsmåte for fremstilling av et farmasöytisk tålbart pyridiniumsalt
HU893527D0 (en) Process for the production of proburzine and pharmaceutical preparations containing thereof

Legal Events

Date Code Title Description
SPCF Filing of supplementary protection certificate

Free format text: PRODUCT NAME: PAMORELIN. PULVER OG VAESKE TIL DEPOTINJEKSJONSVAESKE, SUSPENSJON 11,25 MG "IPSEN". 2 ML FERDIGBLANDET SUSPENSJON INNEHOLDER 11,25 MG TRIPTORELIN, SOM TRIPTORELINPAMOAT, HVER MILLILITER FERDIGBLANDET SUSPENSJ ON INNEHOLDER 5,625 TRIPTORELIN, SOM TRIPTORELINPAMOAT; NAT. REG. NO/DATE: DE , MT04-2772 20041118; FIRST REG.NO/DATE: DE , 553940000 20040316

Spc suppl protection certif: 2005012

Filing date: 20050503

MK1K Patent expired
SPCG Granted supplementary protection certificate

Free format text: PRODUCT NAME: PAMORELIN. PULVER OG VAESKE TIL DEPOTINJEKSJONSVAESKE, SUSPENSJON 11,25 MG "IPSEN". 2 ML FERDIGBLANDET SUSPENSJON INNEHOLDER 11,25 MG TRIPTORELIN, SOM TRIPTORELINPAMOAT, HVER MILLILITER FERDIGBLANDET SUSPENSJ ON INNEHOLDER 5,625 TRIPTORELIN, SOM TRIPTORELINPAMOAT; NAT. REG. NO/DATE: DE , MT04-2772 20041118; FIRST REG.NO/DATE: DE , 553940000 20040316

Spc suppl protection certif: 2005012

Filing date: 20050503

Extension date: 20130919

SPCX Expiry of an spc

Spc suppl protection certif: 2005012

Effective date: 20130919